|Bid||64.51 x 1000|
|Ask||65.30 x 800|
|Day's Range||61.66 - 65.69|
|52 Week Range||38.94 - 86.95|
|Beta (5Y Monthly)||1.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 08, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||83.54|
Subscribe to Yahoo Finance Plus to view Fair Value for CRSPLearn more
No matter what the economy is doing, healthcare stocks make a great long-term bet. Intuitive Surgical (NASDAQ: ISRG) is the global leader in robotic surgery. Today, Intuitive has an installed base of more than 7,700.
CRISPR Therapeutics (NASDAQ: CRSP) has been making headlines lately as a result of its groundbreaking gene-editing collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX). The backstory is that the two companies recently filed for a spate of regulatory approvals for the CRISPR/Cas9 gene-edited product, exa-cel, as a functional cure for two rare blood disorders, sickle cell disease and transfusion-dependent beta thalassemia. What arguably hasn't been appreciated, however, is CRISPR's other clinical assets in immuno-oncology, regenerative medicine, and in vivo therapeutics.
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...
Disruptive companies often deliver the largest investment returns as they transform industries and grow into giants. Of course, for every Alphabet, Meta Platforms, and Amazon, there are hundreds of promising businesses that flame out. Investors with high risk tolerance need to consider market opportunity and competitive advantages when choosing where to put their money.
The next 12 months could be dicey for the economy and the stock market, especially as the U.S. Federal Reserve recently predicted a recession could come by year-end. CRISPR Therapeutics is a gene-editing-focused biotech with no product on the market. The company has submitted regulatory applications for its leading candidate, exa-cel, in the U.S. and Europe.
Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE). David Jagielski (CRISPR Therapeutics): Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off. The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.
It's important to take a look at the company's long-term prospects and its path to get there. The other is an innovative biotech with potentially exciting news on the horizon. Carnival (NYSE: CCL) (NYSE: CUK) is bouncing back after a tough time during the early pandemic days.
Gene-editing healthcare therapies and renewable energy are two of the strongest trends today and for the next few years. Both sectors are worthy of sizable investments, particularly if you're looking to make long-term investments. CRISPR (clustered regularly interspaced short palindromic repeats) gene editing was discovered in 2012, and has the potential to revolutionize some aspects of health care.
CRISPR Therapeutics (NASDAQ: CRSP) and Teladoc Health (NYSE: TDOC) both score a win when it comes to innovation in healthcare. CRISPR has developed a gene-editing approach that aims to fix faulty genes responsible for disease. Teladoc leads in telemedicine, allowing patients to visit doctors from the comfort of an armchair at home.
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
On May 10, Cathie Wood's ARK Innovation ETF (NYSEMKT: ARKK) made two sales of CRISPR Therapeutics (NASDAQ: CRSP) stock, dumping more than 249,500 shares. In case you're out of the loop, CRISPR Therapeutics is a clinical-stage biotech company that's using the CRISPR-Cas9 gene editing system that it's named after to create treatments for hereditary hematologic disorders, cancers, and even diabetes. Its lead program, exa-cel, is currently being reviewed by regulators at the U.S. Food and Drug Administration (FDA), and if it gets approved, it will be used to treat both sickle cell disease and beta thalassemia, a pair of hereditary blood disorders.
Last year, the stock market went into a downward spiral, and growth stocks as a group were dragged down more than most. This year, the stock market appears to be recovering. Before their likely rebounds make them too expensive, here are two growth stocks to consider investing in now.
The Vanguard Growth ETF has already gained 19% in 2023. For investors with either CRISPR Therapeutics (NASDAQ: CRSP) or Nanox (NASDAQ: NNOX) in their portfolios, it's already been a great year. Shares of CRISPR Therapeutics are up more than 57% since the end of 2022.
Gene editing firm CRISPR Therapeutics has rallied since it reported earnings last Monday. Let's check out the charts. In this daily bar chart of CRSP, below, I see a bullish set up. Prices trade above the rising 50-day moving average line and above the still declining 200-day moving average line.
A year ago, CRISPR Therapeutics' (NASDAQ: CRSP) stock was trading for $46 per share. As of Tuesday afternoon, the biotech stock was at $64. While other investors have begun to catch on to the upside of the company, it's still a clinical-stage biopharmaceutical company -- that is, one with no marketed therapies yet.
Despite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week. The tech-heavy Nasdaq Composite, for instance, edged higher by nearly 3% during the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. Among the best performers within the growth stock landscape this week were biopharmaceuticals.
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. CRISPR Therapeutics cleared that benchmark Wednesday, with a jump from 69 to 89 Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
CRISPR Therapeutics ( NASDAQ:CRSP ) First Quarter 2023 Results Key Financial Results Revenue: US$100.0m (up by US$99.1m...
Thanks to the gene-editing pioneer having a pipeline chock-full of deep value and a possible regulatory approval on tap, investors are bidding up shares today.
CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates.
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 59.88% and 165.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
-Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD)- -EU and U.K. submissions validated by European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA); exa-cel has been granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the MHRA- -Enrollment and dosing ongoing for CTX110®,
Growth stocks have performed surprisingly well in 2023. Despite ever-rising interest rates, a possible recession, and a regional banking crisis, the growth-oriented Nasdaq Composite has ticked higher by an impressive 14.8% so far this year. Which growth stocks ought to continue to march northward in the second quarter of the year and beyond?
Healthcare stocks always make a great addition to long-term portfolios. Most of us know Pfizer (NYSE: PFE) well for one particular product -- the COVID-19 vaccine. After all, the company dominates the market and has brought in billions of dollars in revenue from the vaccine over the past two years.
On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.